Illumina, Inc. (NASDAQ: ILMN) announced the appointment of Daniel M. Skovronsky, MD, PhD, to its Board of Directors, effective June 16, 2026.

Dr. Skovronsky currently serves as Chief Scientific and Product Officer of Eli Lilly and Company and President of Lilly Research Laboratories, where he leads the company's global research and development organization. He also oversees commercial products across Lilly Cardiometabolic Health, Lilly Immunology, and Lilly Neuroscience.

He joined Eli Lilly in 2010 following the acquisition of Avid Radiopharmaceuticals, a company he founded in 2004 and led as chief executive officer. He previously served on the Board of Directors of Myriad Genetics, Inc.

Illumina CEO Jacob Thaysen said in a statement: "His experience building and advancing large research portfolios gives our Board a perspective that can help strengthen Illumina's ability to drive innovation across genomics, multiomics, and precision medicine."

Dr. Skovronsky holds a Bachelor of Science in molecular biophysics and biochemistry from Yale University and earned both his MD and PhD from the University of Pennsylvania, where he also completed residency training in pathology and fellowship training in neuropathology.